Taro Pharmaceutical Industries (NYSE:TARO) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
Separately, HC Wainwright began coverage on Taro Pharmaceutical Industries in a research report on Monday. They set a “buy” rating and a $124.00 price target for the company. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $124.00.
Shares of Taro Pharmaceutical Industries (NYSE TARO) traded up $0.89 during mid-day trading on Wednesday, reaching $101.35. The company’s stock had a trading volume of 41,435 shares, compared to its average volume of 92,079. Taro Pharmaceutical Industries has a one year low of $93.01 and a one year high of $128.46. The firm has a market cap of $4,091.21, a price-to-earnings ratio of 19.68 and a beta of 0.64.
ILLEGAL ACTIVITY WARNING: “Taro Pharmaceutical Industries (TARO) Upgraded by ValuEngine to Hold” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://stocknewstimes.com/2018/03/14/taro-pharmaceutical-industries-taro-upgraded-by-valuengine-to-hold.html.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.